These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 22432116)

  • 1. High burden of kidney disease in youth-onset type 2 diabetes.
    Dart AB; Sellers EA; Martens PJ; Rigatto C; Brownell MD; Dean HJ
    Diabetes Care; 2012 Jun; 35(6):1265-71. PubMed ID: 22432116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.
    Fernández-Juárez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Lahera V; Casas L; Oliva J;
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1870-6. PubMed ID: 24135218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteinuric renal disease in type 2 diabetes-is remission of proteinuria associated with improved mortality and morbidity?
    Tan J; Jaung R; Gamble G; Cundy T
    Diabetes Res Clin Pract; 2014 Jan; 103(1):63-70. PubMed ID: 24380605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy.
    Fernández-Juárez G; Villacorta Perez J; Luño Fernández JL; Martinez-Martinez E; Cachofeiro V; Barrio Lucia V; Tato Ribera AM; Mendez Abreu A; Cordon A; Oliva Dominguez JA; Praga Terente M
    Nephrology (Carlton); 2017 May; 22(5):354-360. PubMed ID: 27003829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
    Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventing end-stage renal disease.
    Mogensen CE
    Diabet Med; 1998; 15 Suppl 4():S51-6. PubMed ID: 9868993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ongoing treatment with renin-angiotensin-aldosterone-blocking agents does not predict normoalbuminuric renal impairment in a general type 2 diabetes population.
    Afghahi H; Miftaraj M; Svensson AM; Hadimeri H; Gudbjörnsdottir S; Eliasson B; Svensson MK;
    J Diabetes Complications; 2013; 27(3):229-34. PubMed ID: 23246248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central hemodynamics are associated with cardiovascular disease and albuminuria in type 1 diabetes.
    Theilade S; Hansen TW; Rossing P
    Am J Hypertens; 2014 Sep; 27(9):1152-9. PubMed ID: 24627444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians.
    Pavkov ME; Bennett PH; Knowler WC; Krakoff J; Sievers ML; Nelson RG
    JAMA; 2006 Jul; 296(4):421-6. PubMed ID: 16868300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current update in the management of diabetic nephropathy.
    Van Buren PN; Toto R
    Curr Diabetes Rev; 2013 Jan; 9(1):62-77. PubMed ID: 23167665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses.
    Williams ME; Lacson E; Wang W; Lazarus JM; Hakim R
    Clin J Am Soc Nephrol; 2010 Sep; 5(9):1595-601. PubMed ID: 20671217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors.
    Andrésdóttir G; Jensen ML; Carstensen B; Parving HH; Rossing K; Hansen TW; Rossing P
    Diabetes Care; 2014 Jun; 37(6):1660-7. PubMed ID: 24623028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes.
    Lytvyn Y; Bjornstad P; Lovshin JA; Boulet G; Farooqi MA; Lai V; Tse J; Cham L; Lovblom LE; Weisman A; Keenan HA; Brent MH; Paul N; Bril V; Advani A; Sochett E; Perkins BA; Cherney DZI
    Am J Kidney Dis; 2019 Jun; 73(6):786-796. PubMed ID: 30799029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.
    Schjoedt KJ; Andersen S; Rossing P; Tarnow L; Parving HH
    Diabetologia; 2004 Nov; 47(11):1936-9. PubMed ID: 15551047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
    Burnier M; Zanchi A
    J Hypertens; 2006 Jan; 24(1):11-25. PubMed ID: 16331093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined pancreas-kidney transplantation for patients with end-stage nephropathy caused by type-2 diabetes mellitus.
    Margreiter C; Resch T; Oberhuber R; Aigner F; Maier H; Sucher R; Schneeberger S; Ulmer H; Bösmüller C; Margreiter R; Pratschke J; Öllinger R
    Transplantation; 2013 Apr; 95(8):1030-6. PubMed ID: 23407544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy.
    Hirst JA; Taylor KS; Stevens RJ; Blacklock CL; Roberts NW; Pugh CW; Farmer AJ
    Kidney Int; 2012 Apr; 81(7):674-83. PubMed ID: 22189841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morbidity and mortality in young-onset type 2 diabetes in comparison to type 1 diabetes: where are we now?
    Wong J; Constantino M; Yue DK
    Curr Diab Rep; 2015 Jan; 15(1):566. PubMed ID: 25398205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive treatment and mortality in diabetic patients. What is the evidence?
    Sawicki PT; Heise T; Berger M
    Diabetologia; 1997 Jul; 40 Suppl 2():S134-7. PubMed ID: 9248721
    [No Abstract]   [Full Text] [Related]  

  • 20. An evaluation of renin-angiotensin system markers in youth with type 2 diabetes and associations with renal outcomes.
    Dart AB; Wicklow B; Scholey J; Sellers EA; Dyck J; Mahmud F; Sochett E; Hamilton J; Blydt-Hansen T; Burns K
    Pediatr Diabetes; 2020 Nov; 21(7):1102-1109. PubMed ID: 32657529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.